At Apellis, we pride ourselves on compassion, revolutionary science, and contributions to humankind around the world. Sound like you? Learn how to join our team: https://bit.ly/40XVZSP #WeAreApellis #TeamApellis
Apellis Pharmaceuticals
生物技术研究
Waltham，MA 73,103 位关注者
Global biopharma company leveraging courageous science, creativity, and compassion to deliver life-changing therapies.
关于我们
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: https://bit.ly/476Q8
- 网站
-
https://apellis.com/
Apellis Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Waltham，MA
- 类型
- 上市公司
- 创立
- 2008
- 领域
- Targeted C3 Therapies、Complement System、Hematology、Ophthalmology、Nephrology、Paroxysmal Nocturnal Hemoglobinuria (PNH)、Geographic Atrophy (GA)、C3 Glomerulopathy (C3G)、Cold Agglutinin Disease (CAD)、Gene Therapy、Neurology和Amyotrophic Lateral Sclerosis (ALS)
地点
Apellis Pharmaceuticals员工
-
Beth Marsh
Commercial Strategy and Launch | Sales Management | Business Development | Training & Development
-
Alexandre de Jesus
Associate Director @ Apellis Pharmaceuticals | Commercial Operations Excellence
-
Renaud Desgraz, PhD
-
Lisa Paul-Stark
Patient focused rare disease medical sales professional with over 20 years of success, including more than 18 years in rare/Orphan disease, focusing…
动态
-
Test your #GeographicAtrophy (GA) knowledge with our latest #ApellisEyeQ poll!
此处无法显示此内容
在领英 APP 中访问此内容等
-
At Apellis, we advance courageous science to deliver life-changing medicines for some of the most challenging diseases patients face. Our researchers have studied complement for over 20 years and are leading the field in targeted C3 therapies. Learn more about our revolutionary science at https://bit.ly/45NXkLy #WeAreApellis
-
-
November is National Family Caregivers Month. We’re proud to partner with people like Beth Ann, caregiver to her son Chase with C3G, to champion the patient voice through everything we do. Learn more about their story at https://bit.ly/3YmAXuc #WeAreApellis?
-
-
Thank you to the American Society of Nephrology for an amazing weekend of collaboration and connection at #KidneyWk! In case you missed it, learn more about our work in C3G and IC-MPGN at https://bit.ly/3YmAXuc. #WeAreApellis
-
-
We’re thrilled to share positive results from our Phase 3 VALIANT study at the American Society of Nephrology (ASN) #KidneyWk Meeting. Read the full press release here: https://bit.ly/3YFct0O ? Results were presented as an oral presentation during the High-Impact Clinical Trials session. There are currently no approved treatments for C3G or IC-MPGN – rare kidney diseases which can lead to kidney failure within five to 10 years of diagnosis.
-
-
C3G and IC-MPGN are rare diseases that can lead to kidney failure within five to 10 years of diagnosis, requiring patients to go on life-long dialysis or get a kidney transplant. Attending #KidneyWk? Learn how Apellis is innovating to help patients like Chase who are living with C3G at booth #2113. #WeAreApellis ?
-
Attending the American Society of Nephrology Annual Kidney Week meeting this week? Come to booth #2113 to learn about our data in C3G and IC-MPGN, which are rare kidney diseases with no approved treatment options. Check out the presentation details: https://bit.ly/4eOoWF4 #WeAreApellis #KidneyWk
-
?? Calling all retina specialists! Still at #AAO2024? Learn more about how to identify and treat #GeographicAtrophy (GA) with our immersive modules at booth #4419.
-
In case you missed it: Today we presented late-breaking data on the efficacy and safety of our #GeographicAtrophy (GA) treatment at #AAO2024 as part of Retina Subspecialty Day. You can check out the full presentation here: https://bit.ly/4hcUrdf